Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

ended September 30, 2008 were $45.4 million compared to $36.0 million for the period of 2007.

Research and development expenses for the three months ended September 30, 2008 totaled $10.1 million compared to $9.1 million for the three months ended September 30, 2007. Research and development expenses for the nine months ended September 30, 2008 totaled $32.6 million compared to $29.6 million for the same period of 2007. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion and MAESTRO-02 and MAESTRO-03 increase in number of patients under treatment. General and administrative expenses were $1.3 million for the three months ended September 30, 2008 compared to $1.1 million for the three months ended September 30, 2007. General and administrative expenses were $11.6 million for the nine months ended September 30, 2008 compared to $5.2 million for the same period of 2007.

As at September 30, 2008, cash and short-term investments totaled $98.8 million compared to $38.0 million at December 31, 2007. As at September 30, 2008, the Company had working capital of $94.0 million (excluding the current portion of deferred revenue which does not represent a cash obligation) compared to $34.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials for which it is responsible under the Lilly agreement.

As at September 30, 2008 there were 91,086,323 common shares, 26,021,528 warrants and 9,161,500 stock options of the Corporation issued and outstanding.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: IPXL).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... July 29, 2014, Impax Laboratories, Inc. (the "Company") issued ...
(Date:7/29/2014)... Calif. , July 29, 2014 /PRNewswire-iReach/ -- ... agreement with FORMA Therapeutics, Inc., to provide access ... proprietary fragment-based lead discovery platform for novel small ... excited about the opportunity to work with FORMA ... of epigenetics and protein homeostasis. FORMA Therapeutics, decision ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 TransVac Solutions, ... linen collection and transport solutions for hospitals, will be ... Healthcare Engineering (ASHE) Annual Conference & Technical Exhibition Aug. ... present its technology for making hospitals cleaner, reducing infection ... over the hospital’s life cycle. Staff will be ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... prescription ... solution, ... new Xtremityscan System and give away a free unit at the ... Xtremityscan is a digital shape acquisition system that allows users ...
... to Create One of the Industry,s Largest eClinical ... ... PAREXEL International,Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical ... plc, a company traded on the London Stock Exchange, ("ClinPhone"),have ...
... June 13 On Thursday, June 19, 2008,at 7:00 ... Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq and MTA: ... of the Annual Meeting,of Shareholders at its Seattle headquarters ... meeting will be webcast live on CTI,s website,at ...
Cached Biology Technology:PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress 2PAREXEL Reaches Agreement To Acquire ClinPhone 2PAREXEL Reaches Agreement To Acquire ClinPhone 3PAREXEL Reaches Agreement To Acquire ClinPhone 4PAREXEL Reaches Agreement To Acquire ClinPhone 5Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008 2
(Date:7/29/2014)... Aarhus University researchers have developed an easier method ... strengthen the work involved in diagnosing diseases. , ... provides a strong partnership that can be used ... conjugates which tag proteins with DNA ... sensitive detection and visualisation of biological material. The ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... bacteria and algae, propel themselves using whip-like appendages ... a millimetre long, function like tiny oars, helping ... cilia are found on the surfaces of many ... liquids over the cell. , Flagella and ... expel pathogens from our airways, they establish the ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3
... Fusarium samples. A Virginia Tech plant pathologist ... detect airborne pathogens above agricultural fields. , ... and weed science in the College of Agriculture ... and engineering with his interdisciplinary research but has ...
... common practice among many college students involves "pulling all-nighters", ... practice associated with lower grade-point averages compared to those ... abstract that will be presented Wednesday at SLEEP 2007, ... Societies (APSS). , "Sleep in college students is generally ...
... a microbial protein to improve water quality. , But ... from potentially toxic nanoparticles in their own environments, and ... the same thing on a larger scale. , ... and Lawrence Berkeley National Laboratory found that bacteria from ...
Cached Biology News:Small, self-controlled planes combine plant pathology and engineering 2Small, self-controlled planes combine plant pathology and engineering 3Microbes at work cleaning up the environment 2
...
...
...
... High Resolution - Efficiently ... 50 to 1000 bp. ... sizing PCR fragments, small ... restriction enzyme digestion, and ...
Biology Products: